Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RedNASH: Empagliflozin for Non-Alcoholic Steatohepatitis
NCT06519448Enrolling by invitation
- Sponsor
- Military University Hospital Prague
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in Nonalcoholic steatohepatitis (NASH), sponsored by Military University Hospital Prague. Primary endpoint: Change in histological activity at 12 months. Started Apr 2024; status: enrolling by invitation.
02
Drugs
empagliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06519448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519448.